Biomarkers Usable in Various Fields Including Prediction, Prognosis, Diagnosis, and Treatment
Basgen Bio, an AI-based bio big data specialized company, announced that it has transferred a time-concept included biomarker for gastric cancer risk assessment (Time-Labeled BioMarker / hereinafter TLBM) to Zencurix, a molecular diagnostics specialized company.
Basgen Bio is discovering new biomarkers incorporating the concept of time based on the largest private genomic cohort of about 160,000 individuals. Recently, it has discovered and validated biomarkers for various diseases including gastric cancer, breast cancer, colorectal cancer, liver cancer, and chronic diseases.
The gastric cancer biomarker being transferred this time was discovered based on genomic cohort data of about 160,000 Koreans and is a novel biomarker not previously reported worldwide. It can identify genetic traits with a 17-fold higher risk of gastric cancer occurrence before the age of 60. Unlike existing biomarkers that only indicate relative risk, Basgen Bio’s gastric cancer biomarker uniquely provides information on the risk level at different ages and the remaining time until disease onset, which has been highly praised.
Lee Sol, head of the Genetic Epidemiology Research Institute at Basgen Bio, stated, “TLBM is a biological indicator different from those before, encompassing technologies for disease prediction, prevention, diagnosis, and treatment. As the world is striving to develop new drugs and new medical technologies such as diagnostic kits, we will endeavor to secure more sources capable of discovering biomarkers to enter the R&D market accurately and swiftly.”
Zencurix is a company performing prognostic, companion, and early diagnostic tests. Recently, it has been strengthening its diagnostic test portfolio covering the entire cancer continuum. It is expanding its precision cancer diagnosis portfolio by adding cancer risk prediction tests to existing genetic tests.
A Zencurix representative said, “Future medicine utilizing biomarkers is indispensable. We are currently securing biomarker patents in major overseas countries for global market entry, and the gastric cancer biomarker acquired through this technology transfer will also be used as a key marker. We expect significant business synergy effects between Zencurix’s existing portfolio and this technology introduction.”
Meanwhile, Basgen Bio has secured data from about 480,000 individuals in the UK Biobank in addition to the Korean genomic cohort data, and is focusing on technology protection by filing and registering patents for the core TLBM technology and a genetic information-based drug efficacy simulation system for new drug development.
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
